Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment

Biotechnology and Bioengineering

Volumn 107, Issue 5, 2010, Pages 884-893

  Mendonça, Liliana S ^a,b   Moreira, João N ^a,b   De Lima, Maria C Pedroso ^b,c   Simões, Sérgio ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anti BCR ABL siRNA; CML; Imatinib; Liposomes; Transferrin; Triple targeting

Indexed keywords

ANTI-BCR-ABL SIRNA; CML; IMATINIB; TRANSFERRIN; TRIPLE-TARGETING;

ATMOSPHERIC BOUNDARY LAYER; DISEASES; ENCAPSULATION; LIPOSOMES; PHOSPHOLIPIDS; TROPOSPHERE;

RNA;

BCR ABL PROTEIN; IMATINIB; LIPOSOME; MESSENGER RNA; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG FORMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; ONCOGENE PROTEINS V-ABL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCR; PYRIMIDINES; RNA, SMALL INTERFERING; TRANSFERRIN;

EID: 77958590068     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22858     Document Type: Article

References (49)

1. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. 2004. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2): 728-738.
2. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. 2005. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105(8): 3303-3311.
3. Akhtar S, Benter I. 2007. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59(2-3): 164-182.
4. Azzariti A, Xu JM, Porcelli L, Paradiso A. 2004. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 68(1): 135-144.
5. Beni S, Budai M, Noszal B, Grof P. 2006. Molecular interactions in imatinib-DPPC liposomes. Eur J Pharm Sci 27(2-3): 205-211.
6. Blagosklonny MV. 2005. Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol Sci 26(2): 77-81.
7. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. 2006. Regulation of survivin expression through Bcr-Abl/MAPK cascade: Targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107(4): 1555-1563.
8. Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. 2006. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112(2): 199-207.
9. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. 1997. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2): 187-211.
10. Daniels TR, Delgado T, Helguera G, Penichet ML. 2006a. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121(2): 159-176.
11. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. 2006b. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121(2): 144-158.
12. Deininger MW. 2007. Optimizing therapy of chronic myeloid leukemia. Exp Hematol 35(4 Suppl 1): 144-154.
13. Dykxhoorn DM, Novina CD, Sharp PA. 2003. Killing the messenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4(6): 457-467.
14. Dykxhoorn DM, Palliser D, Lieberman J. 2006. The silent treatment: siRNAs as small molecule drugs. Gene Ther 13(6): 541-552.
15. Goldman JM. 2004. Chronic myeloid leukemia-still a few questions. Exp Hematol 32(1): 2-10.
16. Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M, Bai Y, Izawa K, Kobayashi S, Tomonari A, et al. 2004. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 104(5): 1442-1449.
17. Huang C, Li M, Chen C, Yao Q. 2008. Small interfering RNA therapy in cancer: Mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 12(5): 637-645.
18. Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1(3): 297-315.
19. Ishida T, Iden DL, Allen TM. 1999. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 460(1): 129-133.
20. Kawakami S, Hashida M. 2007. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 22(3): 142-151.
21. Kumar LD, Clarke AR. 2007. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Deliv Rev 59(2-3): 87-100.
22. Li H, Qian ZM. 2002. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22(3): 225-250.
23. Li X, Ruan GR, Lu WL, Hong HY, Liang GW, Zhang YT, Liu Y, Long C, Ma X, Yuan L, et al. 2006. A novel stealth liposomal topotecan with amlodipine: Apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release 112(2): 186-198.
24. Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, Zhang L, Guo W, Wang J, Zhang H, et al. 2008. Copper ion-mediated liposomal encapsulation of mitoxantrone: The role of anions in drug loading, retention and release. Eur J Pharm Sci 34(4-5): 333-344.
25. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. 2006. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5(7): 1854-1863.
26. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. 2007. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-Evidence of schedule-dependent synergy. Urology 69(2): 390-394.
27. Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S. 2010. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21(1): 157-168.
28. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17): 5421-5426.
29. Pasternak G, Hochhaus A, Schultheis B, Hehlmann R. 1998. Chronic myelogenous leukemia: Molecular and cellular aspects. J Cancer Res Clin Oncol 124(12): 643-660.
30. Ponka P, Lok CN. 1999. The transferrin receptor: Role in health and disease. Int J Biochem Cell Biol 31(10): 1111-1137.
31. Romberg B, Hennink WE, Storm G. 2008. Sheddable coatings for long-circulating nanoparticles. Pharm Res 25(1): 55-71.
32. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. 2008. Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin Drug Deliv 5(4): 371-383.
33. Savage DG, Antman KH. 2002. Imatinib mesylate-A new oral targeted therapy. N Engl J Med 346(9): 683-693.
34. Savona M, Talpaz M. 2008. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8(5): 341-350.
35. Saxon DN, Mayer LD, Bally MB. 1999. Liposomal anticancer drugs as agents to be used in combination with other anticancer agents: Studies on a liposomal formulation with two encapsulated drugs. J Lipos Res 9(4): 507-522.
36. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, et al. 2001. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510(1-2): 152-166.
37. Shah NP. 2005. Loss of response to imatinib: Mechanisms and management. Hematology Am Soc Hematol Educ Program 183-187.
38. Szakacs Z, Beni S, Varga Z, Orfi L, Keri G, Noszal B. 2005. Acid-base profiling of imatinib (gleevec) and its fragments. J Med Chem 48(1): 249-255.
39. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. 2007. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 1768(3): 678-687.
40. Visser CC, Stevanovic S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, Crommelin DJ, de Boer AG. 2005. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci 25(2-3): 299-305.
41. Walz C, Sattler M. 2006. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57(2): 145-164.
42. Wang J, Goh B, Lu W, Zhang Q, Chang A, Liu XY, Tan TM, Lee H. 2005. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28(5): 822-828.
43. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. 2001. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9): 1331-1335.
44. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ. 2007. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10(3): 350-357.
45. Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E. 2007. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol 29(2): 126-131.
46. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. 2006. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112(2): 229-239.
47. Zimmermann GR, Lehar J, Keith CT. 2007. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov Today 12(1-2): 34-42.
48. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. 2001. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37(1): 69-82.
49. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. 2005. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: Relevance of the administration sequence. Clin Cancer Res 11(5): 1990-1998.